



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2463815 C 2009/04/07

(11)(21) **2 463 815**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2002/10/18
(87) Date publication PCT/PCT Publication Date: 2003/04/24
(45) Date de délivrance/Issue Date: 2009/04/07
(85) Entrée phase nationale/National Entry: 2004/04/16
(86) N° demande PCT/PCT Application No.: GB 2002/004730
(87) N° publication PCT/PCT Publication No.: 2003/033508
(30) Priorité/Priority: 2001/10/18 (GB0125081.0)

(51) Cl.Int./Int.Cl. *C07F 9/38* (2006.01),
A61K 31/663 (2006.01), *A61P 19/08* (2006.01)

(72) Inventeurs/Inventors:
HAMIED, YUSUF KHWAJA, IN;
RAO, DHANMARAJ RAMACHANDRA, IN;
KANKAN, RAJENDRA NARAYANRAO, IN

(73) Propriétaire/Owner:
CIPLA LTD., IN


(74) Agent: SIM & MCBURNEY

(54) Titre : SELS D'ALENDRONATE PHARMACEUTIQUEMENT ACCEPTABLES PRESENTES SOUS UNE FORME AMORPHE

(54) Title: PHARMACEUTICALLY ACCEPTABLE ALENDRONATE SALTS IN AMORPHOUS FORM

(57) Abrégé/Abstract:

A pharmaceutically acceptable alendronate salt in an amorphous form.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number
WO 03/033508 A1

(51) International Patent Classification⁷: **C07F 9/38**,
A61K 31/663, A61P 19/08

(74) Agents: **WAIN, Christopher, Paul** et al.; A.A. Thornton
& Co., 235 High Holborn, London WC1V 7LE (GB).

(21) International Application Number: PCT/GB02/04730

(22) International Filing Date: 18 October 2002 (18.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0125081.0 18 October 2001 (18.10.2001) GB

(71) Applicant (for all designated States except US): **CIPLA LTD.** [IN/IN]; 289 Bellasis Road, Mumbai Central, Mumbai 400 008 (IN).

(71) Applicant (for MW only): **WAIN, Christopher, Paul** [GB/GB]; A.A. Thornton & Co., 235 High Holborn, London WC1V 7LE (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAMIED, Yusuf, Khwaja** [IN/IN]; Windsor Villa, 2nd Floor, Mumbai 400 026 (IN). **RAO, Dhanmaraj, Ramachandra** [IN/IN]; 204 Shriji Krupa, Swaminarayannagar, Pokhran Road #1, Thane 400 601, Maharashtra (IN). **KANKAN, Rajendra, Narayanrao** [IN/IN]; A 3/5, NBD Society, NSS Road, Mumbai 400 084 (IN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICALLY ACCEPTABLE ALENDRONATE SALTS IN AMORPHOUS FORM

(57) Abstract: A pharmaceutically acceptable alendronate salt in an amorphous form.



WO 03/033508 A1

PHARMACEUTICALLY ACCEPTABLE
ALENDRONATE SALTS IN AMORPHOUS
FORM

This invention relates to pharmaceutically acceptable salts of 4-amino-1-hydroxybutylidene bisphosphonic acid (alendronate salts) in amorphous form and a process of preparing the same.

Alendronate sodium is an inhibitor of bone resorption useful for the treatment of diseases such as Paget's disease and osteoporosis.

Processes used heretofore for the production of alendronate sodium result in a crystalline product. EP 402152 discloses the preparation of alendronate monosodium trihydrate which is crystalline. EP 462663 discloses an improved process for making alendronate and crystalline salts thereof which process avoids the use of a strongly acidic hydrolysis medium. A pharmaceutical composition comprising the anhydrous crystalline form of alendronate sodium is disclosed in WO 96/39149.

In order to facilitate easy formulation into pharmaceutical compositions, high solubility of an alendronate salt, such as alendronate sodium, is desired. High solubility may also be a desirable characteristic in terms of the pharmacological properties of this compound.

The present invention is based on the discovery that pharmaceutically acceptable alendronate salts in an amorphous form are non-hygroscopic and exhibit surprisingly better solubility characteristics as compared to, for example, crystalline alendronate sodium trihydrate. In particular, an alendronate salt in an amorphous form of the present invention dissolves in water at a faster rate than the crystalline material.

There is provided by the present invention, therefore, a pharmaceutically acceptable alendronate salt in an amorphous form. In particular, the present invention is concerned with a monovalent pharmaceutically acceptable alendronate salt in an amorphous form. More particularly, the present invention provides alendronate monosodium in an amorphous form.

The term "amorphous" as used herein denotes a physical state which is not crystalline and may be verified by x-ray diffraction and other means including but not limited to observation

with a polarized light microscope and differential scanning calorimetry. More particularly, an amorphous alendronate salt in accordance with the present invention is preferably essentially free from any crystalline form of alendronate salts.

The present invention provides a pharmaceutically acceptable alendronate salt in an amorphous form, preferably containing less than about 3%, and most preferably less than about 1%, water. In particular, the present invention is concerned with a monovalent pharmaceutically acceptable alendronate salt in an amorphous form, preferably containing less than about 3%, and most preferably less than about 1%, water. More particularly, the present invention provides alendronate monosodium in an amorphous form, preferably containing less than about 3%, and most preferably less than about 1%, water.

The present invention also provides amorphous alendronate monosodium having an X-ray diffraction pattern as shown in the accompanying Figure.

The invention also includes a pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable alendronate salt in an amorphous form (in particular alendronate monosodium in an amorphous form), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The invention also provides a method of inhibiting bone resorption in a patient, which method comprises administering to a patient suffering from or susceptible to bone resorption a therapeutically effective amount of a pharmaceutically acceptable alendronate salt in an amorphous form substantially as herein before described, in particular alendronate monosodium in an amorphous form substantially as herein before described, or a pharmaceutical composition comprising the same substantially as hereinbefore described.

The term "inhibition of bone resorption" as used herein, refers to treatment and prevention of bone loss, especially inhibiting the removal of existing bone, for example through direct or indirect alteration of osteoclast formation or activity. Thus a pharmaceutically acceptable alendronate salt in an amorphous form according to the present invention can, for example, prevent bone loss by the direct or indirect alteration of osteoclast formation or activity and which may increase bone mass in patient treatment populations.

Such methods of treatment according to the present invention are useful in treating bone fractures, defects and disorders which can result from the pathological conditions of osteoporosis, osteoarthritis, Paget's disease, osteomalacia, bone loss resulting from multiple myeloma and other forms of related cancer, bone loss resulting from side effects of disuse, other

medical treatment (such as steroids), rheumatoid-related and age-related loss of bone mass and the like. Methods according to the present invention may have particular utility for the treatment of female patients who are post-menopausal.

The term "treating" or "inhibiting" as used herein with respect to methods of the present invention shall mean providing a patient with an amount of a pharmaceutically acceptable alendronate salt in an amorphous form sufficient to act prophylactically with respect to a disease state substantially as herein before described associated with bone resorption in the patient, and / or providing a patient with an amount of a pharmaceutically acceptable alendronate salt in an amorphous form sufficient to alleviate or substantially eliminate a disease state substantially as herein before described associated with bone resorption in the patient.

In another aspect, the invention provides a process for the production of a pharmaceutically acceptable alendronate salt in an amorphous form (in particular alendronate monosodium in an amorphous form), which process comprises removing solvent from a solution of an alendronate salt, so as to obtain an amorphous product according to the present invention.

In the process of the invention, solvent is removed from the solution of an alendronate salt therein, to form amorphous alendronate according to the present invention. The preferred solvent is water since pharmaceutically acceptable alendronate salts in an amorphous form are not very soluble in other common solvents. In principle, however, any solvent can be used.

The solution of an alendronate salt should be essentially free of any crystalline alendronate salt. The solution can, however, contain some (non-crystalline) suspended alendronate salt so as to form a cloudy solution, although this is not preferred.

The solution of an alendronate salt can be made in any suitable way. For example, it can be prepared by dissolving sodium alendronate, eg trihydrate or anhydrous product, in a solvent. The mixture can be heated to aid in the dissolution: in the case of an aqueous solution, we have found it can be advantageous to heat to about 50°C to 60°C.

Alternatively, an alendronate salt can be formed in situ in the solvent. One example of this is to add sodium hydroxide solution to a suspension of alendronic acid in water to form the alendronate sodium in solution in water. Most preferably, the volume of alendronic acid is suspended in about 30 volumes of water and then the pH is adjusted to about 4.3 to 4.4 with sodium hydroxide.

The solution of an alendronate salt used in the process of the invention will preferably have a volume ratio of an alendronate salt to solvent of about 1:10 to about 1:30 or more,

depending on the solubility in the solvent used. For aqueous solutions, a ratio of about 1:10 is preferred. In general, the less solvent there is present, the less needs to be removed to form the amorphous product, so lower solvent qualities are preferred for this reason.

The removal of solvent can be effected by any suitable means appropriate to the solvent in question, from simple evaporation to more intensive procedures. In the most usual case of aqueous solutions, we prefer to use spray drying. In spray drying aqueous solutions, the inlet temperature is preferably from 120°C to 250°C, the outlet temperature preferably from 70°C to 120°C and the feed rate preferably from 5 to 25 ml/min. However, other temperatures and rates can be used.

The product can be characterised by powder X-ray crystallography. Amorphous alendronate sodium is characterised by the absence of a well defined diffractogram. A typical diffractogram is shown in the accompanying Figure. When observed under a microscope, the amorphous product of the invention is seen as spherical beads whereas, in contrast, crystalline material exhibits rhombic structure. The moisture content of amorphous alendronate sodium of the invention is preferably no greater than about 3% by weight, more preferably less than about 1%. At these moisture contents, the amorphous product is stable.

The following Examples illustrate the process of the invention.

Preparation of Alendronate Sodium Amorphous

Example 1

Alendronate sodium trihydrate 25g in 250 ml of water was heated at 60°C to obtain a clear solution. This solution was spray dried in a Lab Plant Spray Drier SD 05TM with an inlet temperature of 200°C, outlet temperature of 100°C, compressed air rate of 0.3 m³/hr and a feed rate of 15 ml/min, to obtain 20g of the product.

The amorphous product was characterised by powder X-ray diffraction.

Moisture content: less than 1%.

Example 2

Crystalline alendronate sodium anhydrous 25g in 500 ml of water was heated at 50°C to obtain an almost clear solution. This solution was spray dried in a Lab Plant Spray Drier SD 05 with an inlet temperature of 160°C, outlet temperature of 80°C, compressed air rate of 0.3 m³/hr and a feed rate of 8 ml/min, to obtain 18g of the product.

The amorphous product was characterised by powder X-ray diffraction.

Example 3


To a suspension of alendronic acid 25g in 750ml of water was added a 20% solution of sodium hydroxide and pH adjusted to 4.3 to 4.4 to obtain a clear solution. This solution was spray dried in a Lab Plant Spray Drier SD 05 with an inlet temperature of 180°C, outlet temperature of 90°C, compressed air rate of 0.3 m³ /hr and a feed rate of 10 ml/min, to obtain 20g of the product.

The amorphous product was characterised by powder X-ray diffraction.

According to another aspect of the invention, the amorphous alendronate sodium can be formulated into pharmaceutical compositions, for example in the form of tablets (coated or uncoated) or capsules for oral administration. Suitable carriers include, for example sugars, starch and derivatives, cellulose and derivatives, gums and polyalcohols. The compositions may also contain additional ingredients such as lubricants, compression aids, flavours, sweeteners and preservatives.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. Alendronate monosodium in amorphous form.
2. Alendronate monosodium in amorphous form, containing less than 3% water.
3. Alendronate monosodium in amorphous form according to claim 2, containing less than 1% water.
4. Alendronate monosodium in amorphous form, having an X-ray diffraction pattern as shown:



5. A process for the production of alendronate monosodium in amorphous form according to any one of claims 1 to 4, which process comprises removing solvent from a solution of alendronate monosodium by spray drying, so as to obtain alendronate monosodium in amorphous form according to any one of claims 1 to 4.

6. A process according to claim 5, wherein the solvent comprises water.
7. A process according to claim 6, wherein said solution is produced by suspending alendronic acid in water and adjusting the pH using aqueous sodium hydroxide.
8. A pharmaceutical composition comprising alendronate monosodium in amorphous form according to any one of claims 1 to 4, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
9. A use of alendronate monosodium in amorphous form according to any one of claims 1 to 4, or a pharmaceutical composition according to claim 8, in the manufacture of a medicament for inhibition of bone resorption in a patient.
10. A use of alendronate monosodium in amorphous form according to any one of claims 1 to 4, or a pharmaceutical composition according to claim 8, for inhibition of bone resorption in a patient.
11. The use according to claim 9 or 10, wherein the alendronate monosodium or the pharmaceutical composition is for the treatment of fractures, disorders which result from osteoporosis, osteoarthritis, Paget's disease, osteomalacia, osteomalacia, bone loss resulting from multiple myeloma, bone loss resulting from side effects of disuse, steroid treatment, rheumatoid-related and age-related loss of bone mass.

1/1

X-RAY POWDER DIFFRACTION PATTERN OF
ALENDRONATE SODIUM AMORPHOUS

Shimadzu XRD-6000 CuK α (1.54060 Å) 30 kV, 30 mA Slits: DS:1.00 deg, SS:1.00 deg, RS:0.15 mm

Theta-2Theta (deg) Company: X-RAY DIFFRACTION

